- 期刊
A Novel Medical Treatment for Lipid Control in Patients with UnstabIe Angina Pectoris and Statin-Induced Liver Dysfunction
並列摘要
Background: This study aims to evaluate the safety and efficacy of Xuezhikang in the treatment of unstable angina pectoris (UAP) in patients with elevated liver enzymes caused by statins. Methods: Ninety UAP patients with elevated liver enzymes (higher than 3-fold the upper limits of normal caused by statins) were randomly divided into 3 groups: withdrawal of simvastatin (group A), continued taking of simvastatin (group B) and switching to Xuezhikang capsules (group C). Results: Blood lipids and high-sensitivity C-reactive protein (hs-CRP) were measured before and after treatment, and liver enzymes were measured every two weeks. As the liver enzymes of the patients in group A returned to normal, they could again undertake administration of simvastatin. If the liver enzyme levels remained abnormal at four weeks, polyene phosphatidylcholine would be added. The endpoint events of each group were followed -up. After treatment for 4 weeks, the liver enzymes decreased in all of the three groups and there was a significant difference (p ＜ 0.05). However, at 8 weeks the liver enzymes showed no significant difference among the three groups (p ＞ 0.05). The blood lipids and hs-CRP were both reduced in group Band C. The decreased triglyceride and hs-CRP levels and increased high-density lipoprotein cholesterol level in group C were more remarkable than those in group B (p ＜ 0.05). The incidence rate of endpoint events in group A was the highest (p ＜ 0.05) among the three groups. Conclusions: Xuezhikang is safe and effective in the treatment for UAP patients with elevated liver enzymes caused by statins.
延伸閱讀
- Lin, H. H., Wang, C. S., Lin, J. L., Hwang, J. J., & Lin, L. Y. (2013). Effects of Anti-Hypertensive Monotherapy with Either Calcium Channel Blocker or Angiotensin Receptor Blocker on Arterial Stiffness, Central Hemodynamics, and Ventriculo-Arterial Coupling in Uncomplicated Hypertension Patients. Acta Cardiologica Sinica, 29(1), 19-27. https://www.airitilibrary.com/Article/Detail?DocID=10116842-201301-201302180006-201302180006-19-27
- Yeh, M. L. (2019). Pegylated interferon combined with ribavirin or all-oral direct acting antivirals therapy for chronic hepatitis B and C dual-infection – A cohort study [doctoral dissertation, Kaohsiung Medical University]. Airiti Library. https://www.airitilibrary.com/Article/Detail?DocID=U0011-0507201914532600
- Kraja, B., Sina, M., Mone, I., Pupuleku, F., Babameto, A., Prifti, S., & Burazeri, G. (2012). Predictive Value of the Model of End-Stage Liver Disease in Cirrhotic Patients with and without Spontaneous Bacterial Peritonitis. Gastroenterology Research and Practice, 2012(), 590-594-089. https://doi.org/10.1155/2012/539059
- 顏榮信、楊啓瑞、郭惠齡、陳容珍、嚴美華、施智源、吳聖良（2010）。An Analysis of Unscheduled Prophylactic Antibiotic Administration in Surgical Procedure and Improvement in a Medical Center。感染控制雜誌，20(5)，273-281。https://doi.org/10.6526/ICJ.201010_20(5).0001
- Huang, W. Y., Liu, C. S., Tsai, J. J., & Wu, H. M. (2014). Effects of Lamotrigine Monotherapy on Lipid Peroxidation and the Antioxidant Defense System in Patients with Newly Diagnosed Epilepsy. The Changhua Journal of Medicine, 12(1), 9-16. https://www.airitilibrary.com/Article/Detail?DocID=16801504-201403-201411060022-201411060022-9-16